Navigation Links
GeNO LLC Announces New Patent for Nitric Oxide Delivery System
Date:6/9/2011

COCOA, Fla., June 9, 2011 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held, advanced development-stage technology company, today announced it has been awarded a new patent for its NITROSYL™ (Inhaled Nitric Oxide) Systems.  U.S. Patent No. 7,947,227, GeNO's seventh patent, concerns a method of providing a therapeutic amount of nitric oxide (NO) to a mammal in a manner that converts nitrogen dioxide (NO2) to nitric oxide (NO).  The NO2 can originate from either a gas bottle or a liquid source. This new patent is set to expire in August 2029.

"It is unusual for a drug already in Phase II clinical trials to have the core technology protected by patents that still have at least 18 years of life," said GeNO LLC Founder and President David Fine.   "This patent further solidifies the strong intellectual property foundation of the company and is an important milestone for the development of our novel NITROSYL Systems."

GeNO's NITROSYL™ Systems aim to add a valuable option for clinicians treating a range of serious pulmonary diseases with inhaled nitric oxide. GeNO's plans for both in-hospital and ambulatory inhaled nitric oxide systems would help address the cost, complexity and lack of portability of current treatment regimens, and would potentially reach a much larger group of patients.

Additional study details can be found on http://clinicaltrials.gov/ -- ClinicalTrials.gov Identifiers NCT01092559 and NCT01265888.  

ABOUT GENO LLC

GeNO LLC, founded in 2006, is a privately held, advanced development-stage technology company that is developing innovative nitric oxide (NO) generation and delivery platforms to enable the true potential of inhaled nitric oxide to be realized. The company is focused on applying the new technology to deliver inhaled nitric oxide to patients in a wide variety of settings, including ambulatory and in-home use for potential chronic treatment. GeNO's NITROSYL Systems will be regulated by the FDA as new drugs with their own NDAs. These systems have been designated as Combination Products by the FDA Office of Combination Products, with the Division of Cardiovascular and Renal Products designated as the lead reviewer for GeNO's initial INDs. The company has seven US patents with numerous additional patent applications pending.

Media Contacts:
Carla Burigatto, 610-457-2178
cburigatto@gmail.com
Brian Heffron, 781-799-9568
bheffron@ctpboston.com


'/>"/>
SOURCE GeNO LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... GERMANTOWN, Md. , and GAITHERSBURG, Md. ... XON ), a leader in the engineering and ... health of the planet, today announced that it has entered ... (NASDAQ: GNVC ), a clinical-stage company and pioneer ... Intrexon intends to integrate and expand upon GenVec,s expertise ...
(Date:1/24/2017)... 2017   QR Pharma , Inc., a ... therapies for the treatment of Alzheimer,s, Parkinson,s and ... four world-class key opinion leaders to its Scientific ... Pharma,s previous roster of impressive advisors in order ... the development of the breakthrough mechanism of action ...
(Date:1/24/2017)... Jan 24, 2017 Research and Markets has ... - Sensor, Actuator - Forecast to 2025" report to their ... Global ... 17.6% over the next decade to reach approximately $76.24 million by ... is witnessing include growing count of labs using optogentic techniques for ...
Breaking Medicine Technology:
(Date:1/24/2017)... York, New York (PRWEB) , ... January 24, 2017 , ... ... for Brazilian butt lifts is on the rise. According to the American Society ... augmentations since 2000. On average, these procedures are performed every 30 minutes of every ...
(Date:1/24/2017)... PA (PRWEB) , ... January 24, 2017 , ... ... showcase its newest technology offering, Processing Assurance Control Equipment (PACE), at the International ... 2, 2017. , PeroxyChem’s booth will highlight the new technology that is used ...
(Date:1/24/2017)... ... January 24, 2017 , ... Twelve startups have been ... 2017 Cupid's Cup Entrepreneurship Competition. Chaired by Under Armour Founder and CEO Kevin ... will showcase their businesses on February 6, 2017, at Under Armour’s global headquarters ...
(Date:1/24/2017)... ... January 24, 2017 , ... Bellus Medical, a leader in medical aesthetics, today ... his new role Dr. Dobke will provide physician oversight for in-house clinical studies and ... of Plastic Surgery and Associate Professor of Surgery at UC San Diego Health and ...
(Date:1/24/2017)... ... January 24, 2017 , ... Inspiration, ... , Well-meaning studies such as the Fordham Institute’s High Stakes for High ... students, such as including gifted or high-achieving students as a subgroup and reporting ...
Breaking Medicine News(10 mins):